Mount Sinai study shows flavoprotein fluorescence could serve as new biomarker
Black patients have a dramatically higher risk of advanced vision loss after a new diagnosis of primary open angle glaucoma (POAG) when compared to white patients, according to a new study from New York Eye and Ear Infirmary of Mount Sinai (NYEE).
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.
Frequent caffeine intake could more than triple risk of glaucoma for those genetically predisposed to higher eye pressure
The finding could lead to new ways to prevent cold sores and herpes-related eye disease from reoccurring, the researchers report.
Following a long-term diet that’s low in carbohydrates and high in fat and protein from vegetables may lower the risk of the most common subtype of glaucoma
Research to Prevent Blindness announces exciting changes to its flagship grant, the RPB Career Development Award, by increasing both the amount of funding and the number of awards funded.
A new artificial intelligence (AI) algorithm developed by researchers at New York Eye and Ear Infirmary of Mount Sinai (NYEE) can rapidly and accurately detect age-related macular degeneration (AMD), a leading cause of vision loss in the United States.
Teprotumumab, the first FDA-approved medicine for thyroid eye disease, provides significant improvement in eye bulging, regardless of patient gender, age or smoking status, according to a study accepted for presentation at ENDO 2020, the Endocrine Society’s annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.
Researchers at Case Western Reserve University, funded in part through a Gund-Harrington Scholar grant at University Hospitals in Cleveland, have used used chemically modified lipids—instead of the viruses most commonly used as carriers— to safely deliver gene therapy to fight a rare, but irreversible, genetic eye disorder known as Stargardt disease.
It would be the first treatment for “dry” age-related macular degeneration and could significantly improve treatment for wet AMD.
With $9.7 million in funding from the National Eye Institute, researchers at the University of Illinois at Chicago will study the impact of chronic eye disease among Latinos.
Researchers at the IU School of Optometry have used adaptive optics technology to create the first undistorted microscopic images of the eye’s trabecular meshwork, which could help improve treatment for glaucoma.